MediChem Life Sciences Announces Extension of Collaboration With Bristol-Myers Squibb Copmpany
MediChem Life Sciences (NASDAQ: MCLS), a Chicago-based drug discovery technology and services company, today announced that it has renewed its collaboration with Bristol Myers Squibb Company (NYSE: BMY), a pharmaceutical and related health care products company.
MediChem’s medicinal chemistry scientists will use its BLOCKbuilder™ program to provide Bristol-Myers Squibb’s parallel synthesis teams in Wallingford, Conn., and Princeton, N.J., with unique building blocks, monomers and scaffolds. Financial terms of the collaboration were not disclosed.
MediChem developed its BLOCKbuilder™ program for the efficient synthesis of multi-gram quantities of unique building blocks, monomers and scaffolds. MediChem designs and synthesizes building blocks for its clients’ parallel synthesis groups to speed up their drug discovery efforts.
"Our BLOCKbuilder™ program helps our clients break through bottlenecks," said Michael T. Flavin, Ph.D., president and CEO of MediChem. "With gram quantities of the right synthetic building blocks in hand, our clients’ parallel synthesis programs move more quickly."
"The MediChem collaboration has accelerated our efforts to expand and further diversify our compound deck," said Edward Petrillo, Ph.D., vice president, lead discovery and early discovery chemistry at Bristol-Myers Squibb. "We have had great results during the first year of the collaboration and we look forward to continuing the relationship."
Most read news
Topics
Organizations
Other news from the department business & finance
These products might interest you

Good Weighing Practice by Mettler-Toledo
Your Concrete Weighing Quality Assurance Plan
GWP Verification service

Milli-Q® Services / MyMilli-Q™ by Merck Life Science
Services & Support for Water Purification Systems
Quality Care, Delivered. In Person & Online

Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Synthesis
Chemical synthesis is at the heart of modern chemistry and enables the targeted production of molecules with specific properties. By combining starting materials in defined reaction conditions, chemists can create a wide range of compounds, from simple molecules to complex active ingredients.

Topic world Synthesis
Chemical synthesis is at the heart of modern chemistry and enables the targeted production of molecules with specific properties. By combining starting materials in defined reaction conditions, chemists can create a wide range of compounds, from simple molecules to complex active ingredients.